Prognostic Role of Lymphocyte-to-C-Reactive Protein Ratio in Patients with Pulmonary Arterial Hypertension
Open Access
- 23 December 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (24) , 7855
Abstract
Background: Inflammation plays a critical role in the prognosis of patients with pulmonary arterial hypertension (PAH). The lymphocyte-to-C-reactive protein ratio (LCR), as a novel inflammatory marker, has not been studied in patients with PAH. The objective of this study was to investigate the prognostic value of the LCR in patients with PAH. Methods: A retrospective cohort study was conducted on 116 patients with PAH diagnosed in Renji Hospital, School of Medicine, Shanghai Jiao Tong University, from January 2014 to December 2018. The primary outcome was a composite endpoint that included lung transplantation, rehospitalization for PAH, and all-cause death. The LCR is the ratio of the blood lymphocyte count to the C-reactive protein concentration. Results: A total of 116 patients with PAH were included in this study, with an average age of 41.53 years; 92.2% were female, and the event rate was 57.8%. Restricted cubic spline analysis confirmed a linear association between the LCR and the risk of clinical worsening events. Multivariate Cox proportional hazards analysis showed that the LCR was significantly negatively associated with clinical worsening events, with hazard ratios and 95% confidence intervals of 0.772 (0.614–0.970). The Kaplan–Meier curve showed that event-free survival decreased significantly when the LCR was less than 1.477. LASSO regression selected four potential predictors, including the LCR, to construct a nomogram. The nomogram had a high predictive strength, with an area under the ROC curve of 0.805 (0.713–0.896). The calibration curves and decision curve analysis indicated that the nomogram had good predictive performance and the ability to guide clinical management. Conclusions: The LCR is a valuable prognostic marker for predicting long-term clinical events in patients with PAH, and the nomogram incorporating the LCR could effectively stratify risk and guide clinical decision making.Keywords
Funding Information
- National Natural Science Foundation of China (82270050)
This publication has 30 references indexed in Scilit:
- The TAK1/JNK axis participates in adaptive immunity by promoting lymphocyte activation in Nile tilapiaFish & Shellfish Immunology, 2024
- Preoperative lymphocyte to C-reactive protein ratio: A new prognostic indicator of post-primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarctionInternational Immunopharmacology, 2022
- Circulating Markers of Inflammation and Angiogenesis and Clinical Outcomes Across Subtypes of Pulmonary Arterial HypertensionThe Journal of Heart and Lung Transplantation, 2022
- Angiopoietin 2 and hsCRP are associated with pulmonary hemodynamics and long-term mortality respectively in CTEPH—Results from a prospective discovery and validation biomarker studyThe Journal of Heart and Lung Transplantation, 2022
- Risk assessment in pulmonary hypertension based on routinely measured laboratory parametersThe Journal of Heart and Lung Transplantation, 2022
- Pulmonary Arterial HypertensionNew England Journal of Medicine, 2021
- Predicting Survival in Patients With Pulmonary Arterial HypertensionChest, 2019
- Usefulness of thrombosis and inflammation biomarkers in chronic thromboembolic pulmonary hypertension—sampling plasma and surgical specimensThe Journal of Heart and Lung Transplantation, 2018
- Missing Data and Multiple ImputationJAMA Pediatrics, 2013
- C-Reactive ProteinJACC, 2009